- /
- Supported exchanges
- / US
- / SCNLF.PINK
Scancell Holdings plc (SCNLF PINK) stock market data APIs
Scancell Holdings plc Financial Data Overview
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Scancell Holdings plc data using free add-ons & libraries
Get Scancell Holdings plc Fundamental Data
Scancell Holdings plc Fundamental data includes:
- Net Revenue: 4 711 K
- EBITDA: -14 514 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-04-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Scancell Holdings plc News
New
Scancell Holdings "well-financed" and continuing to pursue deals
London, UK --News Direct-- Scancell Holdings PLC Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on t...
Investing in Scancell Holdings (LON:SCLP) three years ago would have delivered you a 146% gain
It hasn't been the best quarter for Scancell Holdings plc (LON:SCLP) shareholders, since the share price has fallen 21% in that time. But in three years the returns have been great. In three years the...
Even though Scancell Holdings (LON:SCLP) has lost UK£33m market cap in last 7 days, shareholders are still up 217% over 3 years
Scancell Holdings plc (LON:SCLP) shareholders might be concerned after seeing the share price drop 15% in the last week. In contrast, the return over three years has been impressive. The share price m...
Hedge funds investors own a significant stake of 44% in Scancell Holdings plc (LON:SCLP)
To get a sense of who is truly in control of Scancell Holdings plc (LON:SCLP), it is important to understand the ownership structure of the business. With 44% stake, hedge funds possess the maximum sh...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.